secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001104659-25-026714
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026
--------------------------------------------------------------------------------

- Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.
- Cash $10.6M at Dec 31, 2024; after $21M stock offering, runway extends to Q4 2025.
- Phase 3 early AD trial launched Feb 2025; symptomatic data expected mid-2026, disease-modifying data mid-2027.
- FDA cleared Phase 3 early AD trial Oct 2024 based on Phase 2/3 data showing symptomatic improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/0001104659-25-026714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925026714/tm2510031d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer